All you need to know in one place

SCA Pharma Awarded Multi-Year Contract with Vizient, Supporting Better Drug Accessibility

Windsor, CT, November 1, 2022– SCA Pharma, a nationally recognized leader in the 503B compounded pharmaceuticals outsourcing industry, providing quality, service, and value to hospitals nationwide, has announced today that Vizient has awarded a multi-year agreement to the company for its full range of 503B ready-to-use products. Vizient is one of the nation’s leading health…

SCA Pharma Names Louis Pace as Chief Financial Officer and Chief Information Officer

SCA Pharma, a nationally recognized leader in the 503B compounding pharmaceuticals outsourcing industry providing quality, service, and value to hospitals nationwide, has announced today the addition of Louis Pace as Chief Financial Officer and Chief Information Officer. Pace brings over 30 years of experience serving several successful private equity backed businesses in functional and P&L…

SCA Pharmaceuticals Appoints Chief Commercial Officer

WINDSOR, CONN. (Jan. 28, 2021)– SCA Pharmaceuticals, LLC, announced details last week of their acquisition by The Vistria Group and Excellere. Continuing their strategic growth initiatives, SCA Pharma is announcing the appointment of Mr. Scott Luce as Chief Commercial Officer.  Mr. Luce will provide leadership and oversight of commercial operations as SCA Pharma continues to…

The Vistria Group and Excellere Capital Management Invest in SCA Pharmaceuticals

WINDSOR, CONN. (Jan. 21, 2021) – SCA Pharmaceuticals, LLC (“SCA Pharma”), has entered into a definitive membership interest purchase agreement with The Vistria Group (“Vistria”) and Excellere Partners (“Excellere”). The Vistria Group and Excellere Partners have purchased all of the issued and outstanding equity interests of SCA Pharma. The terms of the transaction were not…